“We’ll Figure It Out” Is Costing Startups More Than They Realize

Most startups don’t fail because the technology doesn’t work. They fail because the path to commercial adoption was never designed.

Why Waiting Feels Safe and Rarely Is

For early-stage founders, delaying commercial structure often feels rational.

Focus on the product. Stay flexible. Avoid locking into assumptions too early.

But across sectors, the data tells a consistent story: commercial misalignment is not a late-stage problem it is an early-stage risk that compounds.

In its 2023 report, “The State of AI in 2023: Generative AI’s Breakout Year,” McKinsey & Company highlighted that while adoption of advanced technologies is accelerating, only a minority of organizations successfully translate pilots into sustained business value.

The constraint is rarely technical capability.
It is the absence of clear pathways to adoption, integration, and economic value.

This gap emerges early often before founders recognize it as a structural issue.

When Technical Momentum Masks Commercial Risk

Early traction can be misleading.

Pilots are secured. Performance metrics look strong. Stakeholders express interest.

But without commercial architecture, that momentum rarely compounds.

Consider Theranos. At its peak, Theranos secured partnerships with major pharmacy chains like Walgreens and positioned its technology as a breakthrough in diagnostic testing. The company moved rapidly into commercial deployment environments before establishing a robust, scalable operational and regulatory foundation.

While the Theranos case is often framed as a failure of scientific integrity, it also highlights a deeper commercial lesson: commercial pathways were pursued without alignment to the underlying realities of deployment, validation, and system integration.

A more structurally instructive pattern emerged across early digital therapeutics startups in the 2010s.

Companies demonstrated measurable clinical outcomes in controlled settings, yet struggled to scale because they lacked integration into reimbursement systems and payer economics.

Without alignment to how healthcare is actually purchased and delivered, even proven solutions failed to achieve widespread adoption.

In both cases, technical or clinical validation outpaced commercial readiness.

What Getting It Right Looks Like

Now compare that with companies that designed commercialization alongside technical development.

Ginkgo Bioworks built its model around structured partnerships from the outset — embedding its platform into customer programs with milestone-based economics and long-term collaboration agreements. This created early revenue visibility while aligning technical development with real market demand.

A particularly instructive example comes from Moderna in its early years.

Long before COVID-19 brought global visibility, Moderna structured its growth around strategic partnerships with pharmaceutical companies and government entities, including collaborations with BARDA. These were not simple research pilots, they were capital-backed development programs tied to defined milestones and real-world deployment pathways.

This approach:

• aligned R&D with funded use cases

• created non-dilutive capital pathways

• demonstrated a credible route from platform to product

Similarly, Recursion Pharmaceuticals embedded its AI-driven discovery platform into partnerships with companies like Roche and Bayer.

Rather than validating technology in isolation, Recursion tied its platform to:

• co-development agreements

• milestone-based economics

• shared upside in drug discovery programs

These partnerships generated early validation from credible counterparties while creating a repeatable commercial model investors could underwrite.

Across these examples, the pattern is consistent:

Commercial pathways were engineered in parallel with technical development not after it.

What DIY Commercialization Really Costs

The cost of delaying commercial structure is rarely visible upfront. It accumulates quietly and becomes difficult to unwind.

Common downstream impacts include:

• Pricing anchors that compress long-term margins

• Contracts that limit strategic flexibility

• Investor skepticism during diligence

• Extended renegotiation cycles that burn runway

In its 2019 report, “The Most Innovative Companies 2019: The Rise of AI, Platforms, and Ecosystems,” Boston Consulting Group noted that companies failing to align business models and ecosystem strategies early faced longer paths to scale and significantly higher capital requirements.

From a capital markets perspective, this shows up as execution risk. And execution risk is what investors discount most heavily.

What This Looks Like in Practice

Consider a typical industrial AI startup developing predictive maintenance software.

The “Typical” Pilot

• 3–6 month test at a single facility

• strong performance metrics

• post-pilot report

Outcome: Validation… but no path to rollout.

The pilot ends. Procurement restarts. Momentum resets.

The “Commercially Structured” Pilot

Now contrast that with a structured approach:

• Pilot scoped with operations and procurement stakeholders involved upfront

• Success metrics tied to budget ownership and cost savings thresholds

• Pre-defined expansion pathway if milestones are met

• Early introduction of economic logic, even if pricing is not finalized

Outcome:

• validation + organizational alignment

• defined path to multi-site deployment

• early revenue visibility

• credible signals for investors

Same technology. Completely different commercial outcome.

A Simple Framework: Designing Pilots That Convert

From a practitioner perspective, the most effective pilots consistently follow four principles:

1. Anchor to a Real Buyer: Who owns the budget? What problem are they paying to solve?

2. Design for Deployment, Not Demonstration: What happens if this works? How does it scale operationally?

3. Introduce Economic Logic Early: What value is created? How does that translate into financial impact?

4. Pre-Wire the Conversion Pathway: What triggers expansion? What does deployment look like contractually?

When these elements are in place, a pilot becomes more than a test. It becomes a commercial decision mechanism.

The Role of External Commercial Perspective

External commercial support early is not about accelerating sales.

It is about designing decisions that survive scale.

This includes:

• stress-testing assumptions before they harden

• structuring early agreements that preserve optionality

• aligning technical milestones with commercial inflection points

Founders who delay this perspective often discover, too late, that early decisions have already constrained their trajectory.

Closing Thoughts:

The most expensive commercial mistakes are not the ones founders make intentionally.

They are the ones made implicitly in early pilots, early contracts, and early assumptions that go unchallenged.

Technical progress creates momentum. But only commercial structure allows that momentum to compound.

Early commercial clarity does not slow innovation. It protects the path to scale.

If you're navigating the gap between pilot success and commercial scale, we welcome the conversation.